Great point. Academic and fossilized board. I could not have said it better myself. They do more damage than management, and the woman from JP Morgan should be shot for the last financing they did. This is what always happens especially in Cambridge where they sit around and pontificate and tell each other how smart they are.
Those morons do more harm to smart debate. I ignore that dip. The better focus is on what is happening in China in the energy sector. This is my favorite investment as the company seems to have its act together. Running it up to $2.50 on 13 Million shares was ludicrous but low dollar stocks attract a lot of #$%$. I expect more news real soon.
Sentiment: Strong Buy
Huh??? Didn't Gilead bet $11 Billion on Pharmasett?? They had no drug but clinical trials. SNY made a bet on 121?? Why is it so hard to find another partner for 111? I know of lots of deals being done now and a few private biotechs that have been taken out. Big pharma makes investments and you have to be blind not to see what they are ALL doing with their in-house R&D. They are slashing it and finding outside help. And we have noting working where we are spending tons of capital on that we can't interest anyone? You are deluding yourself. The recent MM 121 data should have tweaked interest somewhere, and for all I know it did. But to drone back to my original thesis, Mulroy and this company is burning through capital and not living up to their promises.
A sure fire way to wreck your investment. I have been there before with a few great pied pipers. I just hope this is not one of them.
You defend this management for no reason.They lavish options on each other as if they were lottery tickets. Why give Mulroy 300,000 options for non-performance? You answer that one and you are smarter than I.
You calling me a fool??? Why is our stock at $4.89? I do not care about scientists. They are useless. They run companies like MACK into the ground. They look for agrandisement from their peers. I am looking for the market to recognize us. All the data in the world is not good UNLESS YOU CAN SELL IT!!!!!!!!! #$%$ are we in business for? To write papers in the NEJM? I invested in this company to make MONEY. Not for scientists to get an erection over a Phase II trial that said we are in the right direction.
I have been patient my friend. We all have been. Fidelity has owned 15% of this company for four years. One of these days they and others are going to get fed up with the Mulroy line.
Bob Mulroy is not a scientist. He purports to be a businessman. Best you call him and tell him to act like one or get someone in who knows how!
Then why don't you write to Mulroy and tell him to stop making promises he can't keep. We are not trying to speed up the science. There are some us us who have listened to Bob for three years about partnerships and we have nothing to show for it. The scientific community has not recognized anything for the past three years, but I guess blaming them is easier than blaming incompetent management.
You must have gone to Harvard too.
What makes you think insiders are that smart???? They can't operate on any information that is not public.
Water cooler speak??? GOod luck.
Ever hear of the boy who cried wolf? Bob keeps promising and fails. It is not uncommon in biotech, but at least he should be reasonable and cut our burn. This is a company with shareholders, not a Cambridge research lab with a blank check.
Sad out Board of Directors is so weak.
Boatman..You re either an employee of MACK or Bob's golf partner. For three years that man has been promising a " Sanofi -like " deal and has done nothing.
What do you expect investors and Wall Street to think? Give him accolades for being a nice guy? Leaders lead. It is that simple. You have data and compounds so why are they so difficult to sell? MM 302 looks like an easy drug to partner.
Why does it sit on our shelf? Someone late last year had enough and blasted the stock down to $2.06. You would think management and the Board would have showed concern. So they go out and buy stock. It did nothing. The stock is still in the dumper. FYI. He bought 398 with stock and gave up royalties, but to me the better part of the deal was the nanotechnology, but that is for another day.
The market gives us credit for NOTHING. Network biology is pretty ground breaking but it has not created much except a SNY deal that is in limbo and a pile of compounds we are spending millions on.
You can take all our data and stuff and stick it. The only metric Wall Street wants to see is deals where our technology gets accepted. Until then we are subject to the MM 398 data, which if good will help but not propel us as far as some think.
It is the MM 121 and MM111 that is crucial. As of now Mulroy and the boys are failing us. The SNY is three years old and we have no idea what they plan to do.
I still own a good deal of stock and long term options. But I am getting tired of giving this management more time.
Takeout.Nah..Big Pharma is not that smart. Look at the dopes at Activis who overpaid for Forest Labs. You give them too much credit. You have to impute the value of the potential drugs in order to find compelling value for a takeover, and MACK would not know how to figure that out in a millennium. Their CFO is pretty weak. That said, if a deal is not done in 3-4 months with the MM 121 data now in the public domain I think buy then a lot of potential partners may have looked and passed. It is one reason I wish they would stop the cash burn. I think they have 8 months left net of the 40MM bank loan. One good thing is we will know in a couple of months if 398 works. I even think Sanofi is waiting for the 398 data.
They do own 5% of us.
Bob...do a deal please..Prove my bashing of your leadership wrong!
I have been saying this forever yet a few come to their defense. This stock should have a market cap well over 1 Billion but they are content to pay each other all the options and draw huge salaries and could care less about shareholders. Bob ( no deal ) Mulroy is a nice guy but has no concept of how the investment world looks at his company.
You are full of #$%$. There is no insider SEC filing which is the law. And you violate the law if you post such garbage.
How many drugs have they brought to market using their technology. Of course it is new and for a non-scientist like me I have to go under the assumption that it works as they did a SNY deal. But that is it. They are burning through capital at an enormous clip and have no other deal. MM 398 is nano-technology and not their base of science even though I believe it has a good chance of success. What I meant by not giving a #$%$ is that all of their presentations fall on deaf ears as we are investors. Do you understand the technology? Does it bother you Bob Mulroy has promised a deal for the last two years and has zip to show for it?
I am tired of them touting their technology with only one deal MM 121 and we wait to see what is next there. Have you asked yourself, " What is SNY walks?" This is still a high risk biotech entity with a great bunch of institutions owning the stock. But I see others in the industry with a lot less and better market appreciation than MACK.
DUH??? That press release was for scientists not investors..How about saying what potential the compound has, what is the competition in the space and who else is in it. I have owned MACK for four years and I am an MBA not a Ph.D in molecular biology. 95% of the people who own this stock are not scientists.If you could understand the press release you are a far better man than I, or you are a Ph.D. in something.
Like Mulroy's presentations. This company talks to the wrong crowd, that is why the stock under performs.
I do not give a #$%$ about the science. No one has ever questioned it in peer review papers. I care about what it will lead to and how big the drugs can be.
Our IR/PR is awful..
If you are looking end of month stop looking. This is exciting news where we now have manufacturing capability. The have cash flow and that will obviously grow.The next big will be a major GE deal. i think before June.
Obvious to me they own the coal gassification business in China. Nice pllace to be. My feeling is the end of the year our stock will be in double digits.
Big difference. SYMX has management and a game changing technology. Mack has ZERO management..but great potential. Before the year is out both stocks will be trading at the same price.